Number Т. 16, №3 (63)

Keyword :   CDK4/6 inhibitors

Advantages and risks of using CDK4/6 inhibitors, including palbociclib, in first-line therapy for HR+ metastatic breast cancer
Т. 14, №4 (56)
Assessment of overall survival obtained from the real-world study of using the combination of palbociclib with aromatase inhibitors as a first-line treatment of HR+/HER2− metastatic breast cancer
Т. 13, № 1 (49)